New generative AI tool harnesses insights from earnings, investment power, oil and gas M&A, and what’s driving the energy transition

AUSTIN, Texas, April 25, 2025 /PRNewswire/ — Enverus, the most trusted energy-dedicated SaaS company that leverages generative AI across its solutions, announced it has added Investor Analytics to its suite of offerings. This cutting-edge solution stemming from Enverus’ flagship AI tool, Instant Analyst™, is designed to provide investors with a comprehensive view of key market dynamics. Investor Analytics delivers refined and actionable insights into financials, investor behavior, private equity trends and performance metrics, all vetted by Enverus experts.

This new solution, combined with other offerings like Enverus M&A Analytics for oil and gas deals or Energy Transition M&A, which provides guidance and analytics for navigating energy transition transactions, covers 30 asset types including established power generation assets, CCUS, hydrogen and emerging technologies. Together, these generative AI tools offer comprehensive M&A coverage and knowledge for a vast range of energy deal teams, executives and investors.

Investor Analytics empowers users with timely and actionable insights, enabling them to find answers faster, sharpen their competitive edge and navigate opportunities and risks with greater precision. Investor Analytics will be on full display at EVOLVE 2025, Enverus’ upcoming three-day conference held May 12-15, 2025, at the Hilton Americas in downtown Houston, where visionaries converge to shape the future of energy. EVOLVE will feature more than 65 sessions with 130 speakers focused on technology and energy innovation and exclusive insights from the Enverus Intelligence® Research team. This powerhouse symposium offers unmatched market insights, cutting-edge technological know-how and the chance to connect with industry leaders across the entire energy spectrum.

Continue reading our extended Investor Analytics announcement and EVOLVE 2025

About Enverus
Enverus is the most trusted energy-dedicated SaaS company, with a platform built to maximize value from generative AI, offering anytime, anywhere access to analytics and insights. These include benchmark cost and revenue data sourced from more than 95% of U.S. energy producers and more than 40,000 suppliers. Our platform, with intelligent connections, drives more efficient production and distribution, capital allocation, renewable energy development, investment and sourcing. Our experienced industry experts support our customers through thought leadership, consulting and technology innovations. We provide intelligence across the energy ecosystem: renewables, oil and gas, financial institutions, and power and utilities, with more than 7,700 customers in 50 countries. Learn more at Enverus.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enverus-releases-investor-analytics-refined-actionable-financial-insights-at-your-fingertips-302438614.html

SOURCE Enverus

COLUMBUS, Ohio, April 25, 2025 /PRNewswire/ — Goodwin, an Ohio-based software company built for charter aviation brokers, is proud to announce its official sponsorship of the Cincinnati Bengals’ “Meet the Draft Picks” event for Bengals Premium Suite Holders, taking place this Saturday, April 26.

As a part of its broader partnership with the Bengals’ Suite Program, Goodwin is bringing its spirit of Ohio ingenuity and seamless connectivity to this exclusive event, where the Bengals Premium Suite Holders will get a first look at the Bengals’ 2nd and 3rd round draft picks.

The event timeline includes:

Player introductions and fan meet-and-greetsLive draft insights from Bengals broadcasters Dan Hoard and Dave LaphamBehind-the-scenes tours of the state-of-the-art Kettering Health Performance CenterPhoto ops with Who Dey and the Ben-GalsComplimentary beverages and hors d’oeuvresLive Day 3 NFL Draft coverage

“As a company born and built in Ohio, we’re thrilled to partner with a team that represents the heart of this community,” said Tolga Demirel, Co-Founder of Goodwin. “Our technology is designed to make every connection—from brokers to operators to aircraft—as smooth and intuitive as possible. When things just work, that’s Goodwin Generated.”

Goodwin’s platform is quickly becoming the go-to solution in the charter aviation space, offering a seamless booking and backend support for brokers and operators. By empowering aviation professionals with tools that work smarter, faster and more transparently, Goodwin is helping reshape what modern air travel looks like—starting right here in the Midwest.

The Bengals’ “Meet the Draft Picks” event is the perfect kickoff to a partnership grounded in performance, innovation and Ohio pride.

For more information about Goodwin and its mission, visit www.teamgoodwin.com

About Goodwin

Founded in 2022, Goodwin is headquartered in Ohio with technical talent across the U.S. The company is revolutionizing the charter aviation industry with innovative technology that streamlines charter operations. Goodwin acts solely in a B2B capacity, supporting brokers and operators in digitizing and elevating their workflows, ensuring charter aviation professionals can focus on building meaningful client relationships and scaling their businesses. For more information about how Goodwin is reshaping the charter landscape, please visit www.teamgoodwin.com or follow us on LinkedIn to stay updated.

Media Contact: Clara Armagast
clara@teamgoodwin.com
304-688-5179

View original content to download multimedia:https://www.prnewswire.com/news-releases/goodwin-partners-with-cincinnati-bengals-to-power-meet-the-draft-picks-event-for-bengals-premium-suite-holders-302438634.html

SOURCE Goodwin

Collaboration will deliver innovative AI-powered pathology tools and quality control enhancements to accelerate clinical trials and biomarker discovery

BOSTON and FREDERICK, Md., April 25, 2025 /PRNewswire/ — Precision for Medicine, a leading provider of next generation drug development research and services, and PathAI, a global leader in digital pathology, today announced a strategic collaboration to partner on developing novel AI-based technologies and to integrate PathAI’s advanced digital pathology and analysis capabilities across Precision for Medicine’s clinical trial and biospecimen operations.

This collaboration includes use of several PathAI technologies and establishes an agreement to offer novel tools and analytical services that address emerging needs in biomarker discovery, spatial biology, and tissue-based clinical research. Through this collaboration PathAI’s tools and services will help augment Precision for Medicine’s proprietary pipeline providing biopharma clients with access to imaging workflows offered through Precision for Medicine’s integrated laboratory and clinical trial services.

“Together, we’re deploying tools that add critical quality control steps to tumor biopsy workflows and apply machine-based learning and unsupervised algorithms early in the development cycle to help identify which biomarkers are most relevant for clinical efficacy,” said Darren Davis, PhD, Senior Vice President Global Digital Pathology, Genomics and Liquid Biopsy Solutions. “Precision for Medicine’s CLIA compliant laboratory enables precise patient stratification and accelerate decision-making in clinical trials, ultimately supporting success in areas of high unmet need.”

As part of the agreement, Precision for Medicine will deploy select tools from PathAI, including AISight®, a digital pathology image management system, and other AI-powered algorithms to enhance biospecimen and clinical trial services. These tools will enable the application of validated, algorithm-based quality control steps to biospecimen analysis, improving consistency and data reliability.

The collaboration will also support the use of PathAI’s leading AI capabilities leveraging best in class machine learning based models to enhance Precision for Medicine multi-modal datasets. The technology reduces large, complex biomarker panels to scalable, and actionable, biomarkers to help interpret complex tissue biology to complement translational research programs. Additionally, the companies will work together to analyze complex tissue biology empowering biopharma clients to understand and identify the right patients for the right therapies, faster.

“At PathAI, our mission is to harness the power of artificial intelligence to improve the accuracy, depth, and efficiency of pathology-driven insights,” said Andy Beck, MD, PhD, Co-founder and CEO of PathAI. “We are thrilled to collaborate with Precision for Medicine to help advance our mission and deliver differentiated value to our mutual customers.”

Precision’s collaboration with PathAI brings unique value to biopharma clients by combining these AI tools with proprietary wet lab infrastructure, centralized clinical trial operations, and scientific oversight. The innovative tools generated through this collaboration will only be available through Precision for Medicine’s services, providing a level of integration and customization not offered elsewhere in the industry.

“This collaboration enhances how we’re using our biospecimen business by enabling deeper, more informative analyses of the tissue samples we provide to our clients,” said Cullen Taylor, MD, Medical Director at Precision for Medicine. “We’re adding an entirely new layer of cellular-level insight on top of already well-annotated sequenced samples, going far beyond what traditional pathology assessments can offer. It’s a meaningful step forward in how we support biomarker discovery, enhancing datasets for diagnostic validation and therapeutic development.”

About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research and development services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies a transformational approach to clinical research that integrates clinical trial design and execution with deep scientific knowledge, laboratory expertise, data sciences and advanced manufacturing solutions. This convergence is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine Group, with 3,500 people in 40 locations globally across North America, Europe and Asia-Pacific. For more information, visit precisionformedicine.com

Contact
Andie Lunkenheimer
andie.lunkenheimer@gcihealth.com

About PathAI
PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit pathai.com

Contact
Owen Blaschak
oblaschak@lifescicomms.com

Footnote

1AISight is for Research Use Only in the US; AISight Dx is CE-IVDR in Europe and UKCA in UK

View original content to download multimedia:https://www.prnewswire.com/news-releases/precision-for-medicine-and-pathai-announce-strategic-collaboration-to-advance-ai-powered-clinical-trial-services-and-biospecimen-products-302438551.html

SOURCE PRECISION FOR MEDICINE